Spaans F, Wagenmakers A, Saris W, Reekers A, Theunissen P, Cremers H. Procainamide therapy, physical performance and energy expenditure in the Schwartz-Jampel syndrome.
Neuromuscul Disord 1991;
1:371-4. [PMID:
1822347 DOI:
10.1016/0960-8966(91)90124-b]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effects of procainamide administration were assessed in a 5-yr-old boy with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Without procainamide the resting metabolic rate was found to be significantly higher than in an age-matched control group. With a serum level of 3.8 mg l-1 procainamide a reduction of the resting metabolic rate of 22% was observed, and times needed to climb stairs and to re-open eyes after forceful contraction (blepharospasm) were significantly reduced.
Collapse